Sclerotherapy of benign oral vascular lesion with ethanolamine oleate: an open clinical trial with 30 lesions

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Nov;100(5):579-84. doi: 10.1016/j.tripleo.2004.12.021.

Abstract

Objective: The objective of this study was to report and discuss the results from treatment of benign oral vascular lesions with ethanolamine oleate.

Study design: Twenty-seven patients with 30 examples of oral vascular malformation, hemangioma, or varix were treated with intralesional injections of 1.25% or 2.5% ethanolamine oleate at an interval of 15 days between each application. The lesions were divided into 2 categories: (1) lesions of 20 mm or less and (2) those greater than 20 mm. Subsequently, the Mann-Whitney test was used a means of statistical analysis.

Results: Although the number of injections varied from patient to patient, all lesions responded to the treatment, showing total clinical regression. Lesions of 20 mm or less needed a lesser number of applications than those greater than 20 mm (P < .05).

Conclusions: Ethanolamine oleate is a 100% effective sclerosant agent for treatment of benign oral vascular lesions. In this study, no difference was found between the 2 concentrations applied.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Arteriovenous Malformations / therapy
  • Child
  • Female
  • Hemangioma / therapy
  • Humans
  • Injections, Intralesional
  • Male
  • Middle Aged
  • Mouth Diseases / therapy*
  • Mouth Neoplasms / therapy*
  • Neoplasms, Vascular Tissue / therapy*
  • Oleic Acids / administration & dosage*
  • Sclerosing Solutions / administration & dosage*
  • Sclerotherapy
  • Statistics, Nonparametric
  • Varicose Veins / therapy
  • Vascular Diseases / therapy*

Substances

  • Oleic Acids
  • Sclerosing Solutions
  • ethanolamine oleate